Research Radartracking 1,762 published studies · 471 human · 11 safety signals · 58 clinical trials · 44 cancer pages · updated Sep 2026Open the Research Map →

Research Radar

New PubMed studies on repurposed drugs and natural compounds in cancer — summarized in plain language. A person reviews each one; registered human trials and meta-analyses that pass every automated check post without waiting for that review.

How to read this page. These studies are automatically collected from PubMed and summarized by AI from the abstract. A person reviews them; the strongest tier — registered human trials and meta-analyses that pass every automated check — is posted first and reviewed after. Each summary describes only what that study reported — most are early lab, animal, or small human studies, and findings often conflict. This is educational information, not medical advice, and not a recommendation to take anything. Always talk with your oncologist.
Topic tags. Each study is filed under its main topic. Anticancer studies are the default; these tags flag the other dimensions:
Safety — Safety & interactionsAbsorption (PK) — How it's absorbed (PK)Formulation — Formulation & deliverySupportive care — Symptom & supportive careMetabolism — Metabolism & pathwaysTrial — Clinical trialMechanism — Biomarker & mechanism
Showing studies that mention “pulmonary large cell neuroendocrine carcinoma (lcnec)”.
1 of 200 studies
Human · observationalMechanismMixed resultsLimited evidenceTier 3 · early humann = 590

Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma

Nature communications · Aug 2025 · cohort study (two independent clinical/genomic cohorts)

pulmonary large cell neuroendocrine carcinoma (LCNEC)small cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)

The authors analyzed clinical and molecular data from 590 patients with pulmonary large cell neuroendocrine carcinoma across two cohorts. They identified two genomic subtypes (NSCLC-like with KEAP1/KRAS/STK11 mutations and SCLC-like with RB1/TP53 mutations) and report that 80% of tumors aligned with SCLC transcriptional profiles. The study found elevated FGL-1 and SPINK1 expression in NSCLC-like LCNECs and higher DLL3 in SCLC-like LCNECs, and noted fewer tumor-infiltrating lymphocytes in LCNEC compared with other lung cancers. Overall survival was comparable across chemotherapy, chemoimmunotherapy, and immunotherapy in this cohort.

Reported effect: proportion aligning with SCLC transcriptional profiles 80%, n=590

Key findings
  • Study cohort: 590 patients across two independent cohorts.
  • Comparable overall survival across treatment regimens (chemotherapy, chemoimmunotherapy, immunotherapy) without unexpected adverse events.
  • Genomic analysis identified two LCNEC subtypes: NSCLC-like (KEAP1, KRAS, STK11 mutations) and SCLC-like (RB1, TP53 mutations).
  • 80% of LCNEC tumors aligned with SCLC transcriptional profiles.
  • Serial sampling showed stable mutational landscapes but shifting transcriptomic profiles over time.
  • Elevated FGL-1 (a LAG-3 ligand) and SPINK1 expression were observed in NSCLC-like LCNECs; DLL3 levels were higher in SCLC-like LCNECs.
  • Immunofluorescence confirmed FGL-1 expression in NSCLC-like LCNECs.
  • H&E analyses indicated fewer tumor-infiltrating lymphocytes in LCNECs versus other lung cancers.
  • Authors suggest these immunogenomic features support future investigation of LAG-3, SPINK1, and DLL3-targeted approaches.
Limitations: Observational cohort design — no randomized comparison of treatments reported in the abstract.; Abstract provides no quantitative survival or subgroup outcome measures (no effect sizes or statistical details reported).; Molecular associations (expression of FGL-1, SPINK1, DLL3) are descriptive and do not demonstrate therapeutic efficacy.; Functional or clinical validation of proposed targets is not presented in the abstract.; H&E-based assessment of tumor-infiltrating lymphocytes is a histologic surrogate and may lack detailed immunophenotyping..

Identifies immunogenomic subtypes and candidate targets (FGL-1/LAG-3, SPINK1, DLL3) in LCNEC that may guide future therapeutic investigations.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text